New drug valbenazine tested for Huntington's movement problems
NCT ID NCT06312189
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looks at the long-term safety of valbenazine for people with Huntington disease who have involuntary jerking movements (chorea). It includes 7 participants from Canada who were in a previous valbenazine study. Everyone gets the drug, and researchers track side effects over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- valbenazine
- What this could lead to
- If successful, this could confirm valbenazine as a safe long-term option to reduce involuntary movements in Huntington disease.
- What could go wrong
- This is a very small open-label study with only 7 participants, no placebo group, and focuses on safety rather than effectiveness. Results may not apply broadly.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHOREA, HUNTINGTON are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Neurocrine Clinical Site
Vancouver, British Columbia, V6T 2B5, Canada
-
Neurocrine Clinical Site
Ottawa, Ontario, K1Y 4E9, Canada
-
Neurocrine Clinical Site
Toronto, Ontario, MK2 1E1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.